Intervention: Prednisone
Trial phase: Phase 2 | Phase 3
ATC code: A07EA03 | H02AB07
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 2
Group description: Patients will receive oral cyclophosphamide.

prednisone: <30 mg/day
Eligibility criteria:
Inclusion Criteria:

Diagnosis of acquired hemophilia A in a previously non-coagulopathic individual.
Prior treatment with at least 3 weeks of immunosuppressive therapy
Factor VIII: C levels <50% within 14 days prior to study entry, which do not correct in coagulation assays in which normal plasma is mixed and incubated with patient plasma.
Measurable anti-factor VIII:C antibody inhibitor activity > 0.6 Bethesda Units/ml.
Age ³18 years
Written informed consent
Use of an effective means to avoid pregnancy, including abstinence, for women of childbearing potential,.
Serum bilirubin less than or equal to the upper limit of normal (ULN); ALT and AST £2.5´ ULN within 14 days prior to study entry
Serum creatinine £1.5´ the ULN within 14 days prior to study entry
Negative serum pregnancy test, for all women of childbearing potential, within 14 days prior to study entry

Exclusion Criteria:

Continued treatment requirement of prednisone ≥30mg/day or equivalent dosing of other corticosteroid preparations to control serious symptoms of an underlying autoimmune disease state.
Treatment with cyclophosphamide, danazol, vinca alkaloids, azathioprine, IVIG, or other immunosuppressive, immunomodulatory, or cytotoxic agents (other than decreasing doses of corticosteroids) within 30 days prior to study entry.
Anticipated need for repeated extracorporeal plasmapheresis in order to reverse refractory bleeding associated with acquired hemophilia.
Treatment with other experimental agents within 30 days prior to study entry
Known sensitivity to murine or chimeric products
Hepatitis BsAg positivity or high risk for reactivation of Hepatitis B.
Active infection requiring antibiotic therapy within 7 days prior to study entry
Current use of any required medications, which in the opinion of the treating physician, could be inducing the formation of auto-FVIII:C inhibitory antibodies
Prior treatment with rituximab or other monoclonal antibody therapy
Known HIV antibody positivity
NCI-CTC Grade ³1 cardiac arrhythmia ( refer to CTC v3)
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Currently pregnant women, lactating women, or women within 12 months of delivery, spontaneous miscarriage, or therapeutic or elective termination of pregnancy.
Known severe leucopenia (absolute neutrophil count <1000/µL) or thrombocytopenia (<25,000/µL);
Known pre-existing cystitis or severe urinary outflow obstruction.
Known history of recurrent severe opportunistic infections, eg. generalized herpes zoster;
Inability or unwillingness to comply with study design and requirements and follow-up procedures.